Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (20095)	11/6/2006 11:46:50 AM
From: Galirayo	Respond to of 23958

LOL .. don't loose "sight" of the Big Picture. Italian Undersecretary of State Lauds Collaboration TORONTO--(MARKET WIRE)--Oct 23, 2006 -- On October 20, 2006, Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, together with University Campus Bio-Medico of Rome, Italy, hosted a symposium as an adjunct to the Canadian Diabetes Association Professional Conference and Annual Meetings in Toronto, Canada. The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Generex Oral-lyn(TM)), which is available for sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world. For more information, visit the Generex website at generex.com